Huarte-Muniesa María Pilar, Lacalle-Fabo Esther, Uriz-Otano Juan, Berisa-Prado Silvia, Moreno-Laguna Sira, Burusco-Paternáin María Jesús
Servicio de Aparato Digestivo, Complejo Hospitalario de Navarra, Pamplona, España.
Servicio de Farmacia, Complejo Hospitalario de Navarra, Pamplona, España.
Gastroenterol Hepatol. 2014 Aug-Sep;37(7):389-96. doi: 10.1016/j.gastrohep.2014.02.007. Epub 2014 Apr 12.
Wilson disease (WD) is an inherited disorder that causes copper (Cu) accumulation, leading to mainly liver, neurological and/or psychiatric manifestations. In the absence of some of the typical features, diagnosis of WD is difficult and is based on the combination of clinical, biochemical and genetic testing. The aim of this study was to illustrate the complexity of the approach to WD in daily clinical practice.
We retrospectively analyzed the medical records of patients with WD, including the clinical presentation, histological and biochemical findings, and follow up after treatment. We also carried out genetic testing, and the Leipzig diagnostic score was applied.
We included 15 patients. Four were symptomatic, with liver (n=1), neurological (n=1), psychiatric (n=1) and mixed clinical manifestations (n=1), and 11 were presymptomatic, with elevated transaminases (n=8) and family study (n=3). We observed Kayser-Fleischer ring in 2 patients, both without neurologic symptoms. Ceruloplasmin ≤ 5 mg/dL was present in 73%, and 24-hour urinary Cu> 100 μg in 40%. Liver Cu was >250 μg/g.d.t. in 85% of the patients. The final diagnosis of WD was given by genetic testing (ATP7B gene mutations) in 5 patients with minimal disease features, including one symptomatic patient (psychiatric symptoms). We identified 5 previously reported mutations (p.M645R, p.R827W, p.H1069Q, p.P768L and p.G869R) and 3 unpublished mutations (p.L1313R, p.I1311T and p.A1179D); the most frequent mutation was p.M645R. After treatment, biochemical parameters (transaminases, urinary cooper) and symptoms improved, except in patients with neurological and psychiatric manifestations.
Our series illustrates the important role of genetic testing in the diagnosis of WD. The identification of the p.M645R mutation in most of our patients should be kept in mind in the molecular analysis of the ATP7B gene in our region.
威尔逊病(WD)是一种遗传性疾病,可导致铜(Cu)蓄积,主要引起肝脏、神经和/或精神方面的表现。在缺乏某些典型特征的情况下,WD的诊断较为困难,需综合临床、生化和基因检测结果。本研究旨在阐明日常临床实践中WD诊断方法的复杂性。
我们回顾性分析了WD患者的病历,包括临床表现、组织学和生化检查结果以及治疗后的随访情况。我们还进行了基因检测,并应用了莱比锡诊断评分。
我们纳入了15例患者。4例有症状,分别表现为肝脏症状(n = 1)、神经症状(n = 1)、精神症状(n = 1)和混合临床表现(n = 1),11例为症状前患者,表现为转氨酶升高(n = 8)和家族研究(n = 3)。我们在2例患者中观察到凯泽 - 弗莱舍环,这2例均无神经症状。73%的患者血清铜蓝蛋白≤5mg/dL,40%的患者24小时尿铜>100μg。85%的患者肝脏铜含量>250μg/g.d.t。5例疾病特征轻微的患者,包括1例有症状患者(精神症状),通过基因检测(ATP7B基因突变)确诊为WD。我们鉴定出5个先前报道的突变(p.M645R、p.R827W、p.H1069Q、p.P768L和p.G869R)和3个未发表的突变(p.L1313R、p.I1311T和p.A1179D);最常见的突变是p.M645R。治疗后,除有神经和精神表现的患者外,生化参数(转氨酶、尿铜)和症状均有所改善。
我们的系列研究表明基因检测在WD诊断中具有重要作用。在我们地区对ATP7B基因进行分子分析时,应牢记我们大多数患者中鉴定出的p.M645R突变。